Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pediatric nirmatrelvir + ritonavir study in nonhospitalized symptomatic COVID-19 patients at risk for severe disease
2022-000075-39Phase 2Active
- Sponsor
- Pfizer
- Start
- Apr 2022
- Modality
- Small Molecules, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of Nirmatrelvir and ritonavir in coronavirus disease 2019 (COVID-19), sponsored by Pfizer. Primary endpoint: Pharmacokinetic parameters of nirmatrelvir and ritonavir. Started Apr 2022; status: active.
02
Drugs
Nirmatrelvirritonavir
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on 2022-000075-39.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-000075-39.